On Monday, Kairos Pharma Ltd (AMEX: KAPA) opened higher 4.24% from the last session, before settling in for the closing price of $1.18. Price fluctuations for KAPA have ranged from $0.40 to $4.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -23.37%. Company’s average yearly earnings per share was noted 0.00% at the time writing. With a float of $8.77 million, this company’s outstanding shares have now reached $17.74 million.
Let’s determine the extent of company efficiency that accounts for 4 employees.
Kairos Pharma Ltd (KAPA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Kairos Pharma Ltd is 57.73%, while institutional ownership is 5.32%. The most recent insider transaction that took place on Nov 25 ’24, was worth 318. In this transaction VP of Research and Development of this company bought 200 shares at a rate of $1.59, taking the stock ownership to the 133,057 shares. Before that another transaction happened on Nov 22 ’24, when Company’s Chief Financial Officer bought 2,500 for $1.50, making the entire transaction worth $3,750. This insider now owns 60,796 shares in total.
Kairos Pharma Ltd (KAPA) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.1 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.02) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -29.25% during the next five years compared to -23.37% drop over the previous five years of trading.
Kairos Pharma Ltd (AMEX: KAPA) Trading Performance Indicators
Check out the current performance indicators for Kairos Pharma Ltd (KAPA). In the past quarter, the stock posted a quick ratio of 7.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Kairos Pharma Ltd (KAPA)
Looking closely at Kairos Pharma Ltd (AMEX: KAPA), its last 5-days average volume was 0.54 million, which is a drop from its year-to-date volume of 2.97 million. As of the previous 9 days, the stock’s Stochastic %D was 64.75%.
During the past 100 days, Kairos Pharma Ltd’s (KAPA) raw stochastic average was set at 58.45%, which indicates a significant decrease from 80.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1115 in the past 14 days, which was higher than the 0.0941 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8836, while its 200-day Moving Average is $1.1097. However, in the short run, Kairos Pharma Ltd’s stock first resistance to watch stands at $1.2582. Second resistance stands at $1.2865. The third major resistance level sits at $1.3129. If the price goes on to break the first support level at $1.2035, it is likely to go to the next support level at $1.1771. Now, if the price goes above the second support level, the third support stands at $1.1488.
Kairos Pharma Ltd (AMEX: KAPA) Key Stats
There are currently 20,744K shares outstanding in the company with a market cap of 25.51 million. Presently, the company’s annual sales total 0 K according to its annual income of -2,600 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -1,420 K.
